Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. XCUR
stocks logo

XCUR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2022Q4
3.90M
+84.14%
-0.950
-95.78%
Estimates Revision
Stock Price
Go Up
up Image
+41.89%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Exicure Inc (XCUR.O) is -0.14, compared to its 5-year average forward P/E of -0.82. For a more detailed relative valuation and DCF analysis to assess Exicure Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.82
Current PE
-0.14
Overvalued PE
0.38
Undervalued PE
-2.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
12.85
Current PS
0.00
Overvalued PS
60.86
Undervalued PS
-35.16
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

XCUR News & Events

Events Timeline

(ET)
2025-08-01
16:03:44
Exicure completes last patient in Phase 2 GPC-100 combo trial
select
2025-07-14 (ET)
2025-07-14
11:46:17
Exicure files to sell 5.16M shares of common stock for holders
select
2025-05-28 (ET)
2025-05-28
16:59:56
Exicure receives Nasdaq delinquency notice on late Form 10-Q filing
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-08NASDAQ.COM
Exicure, Inc. Reports Q3 Loss of $2.44 Million

  • Company Performance: Exicure, Inc. reported a loss of -$2.44 million for the third quarter, compared to a loss of -$1.09 million in the same period last year.

  • Earnings Per Share: The earnings per share (EPS) for the quarter was -$0.39, an improvement from -$0.57 per share reported last year.

[object Object]
Preview
9.0
09-12NASDAQ.COM
Stocks of MODD, GALT, XCUR, PEPG, and BSGM Surge in After-Hours Trading Following Clinical Developments and Strategic Actions

  • Modular Medical Inc. (MODD): The stock surged 30.68% to $0.9150 after announcing the completion of a clinical study for its MODD1 insulin pump and plans to submit its Pivot pump to the FDA in October 2025, alongside significant insider buying activity.

  • Galectin Therapeutics Inc. (GALT): The stock rose over 14% to $6.78, continuing a year-to-date gain of over 360%, with CEO Joel Lewis indicating ongoing analysis of biomarkers for their lead candidate, belapectin, which targets MASH cirrhosis and portal hypertension.

  • Exicure Inc. (XCUR): Shares increased 11.11% to $4.00 despite no new announcements, following a wider net loss reported for Q2 2025, as the company pivots its focus to new clinical directions after acquiring GPCR USA.

  • BioSig Technologies Inc. (BSGM): The stock gained 37.08% to $6.10, with an additional rise after announcing its rebranding to Streamex Corp. and a shift in focus towards real-world asset tokenization, including a partnership to develop tokenized gold products.

[object Object]
Preview
9.5
08-09NASDAQ.COM
Exicure Posts Wider Loss in Fiscal Q2

  • Financial Performance: Exicure reported no revenue for the second quarter of 2025, with a net loss widening to $2.6 million due to increased expenses from the acquisition of GPCR Therapeutics USA Inc. The company highlighted an urgent need for additional financing as cash reserves decreased significantly.

  • Business Transition: Following the acquisition, Exicure is shifting its focus towards developing therapeutics for hematologic diseases, particularly targeting stem cell mobilization in blood cancers and genetic disorders, while facing operational challenges and uncertainty regarding future licensing revenue and business transactions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Exicure Inc (XCUR) stock price today?

The current price of XCUR is 6.74 USD — it has increased 21.22 % in the last trading day.

arrow icon

What is Exicure Inc (XCUR)'s business?

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

arrow icon

What is the price predicton of XCUR Stock?

Wall Street analysts forecast XCUR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XCUR is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Exicure Inc (XCUR)'s revenue for the last quarter?

Exicure Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Exicure Inc (XCUR)'s earnings per share (EPS) for the last quarter?

Exicure Inc. EPS for the last quarter amounts to -0.39 USD, decreased -31.58 % YoY.

arrow icon

What changes have occurred in the market's expectations for Exicure Inc (XCUR)'s fundamentals?

The market is revising No Change the revenue expectations for XCUR for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 41.89%.
arrow icon

How many employees does Exicure Inc (XCUR). have?

Exicure Inc (XCUR) has 7 emplpoyees as of December 05 2025.

arrow icon

What is Exicure Inc (XCUR) market cap?

Today XCUR has the market capitalization of 42.48M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free